check quantity

IVISense Transferrin Receptor 750 Fluorescent Probe (Transferrin-Vivo)

Transferrin is an important serum protein that mediates iron transport into cells via the transferrin receptor, a function that is essential for cell growth and metabolism.

PerkinElmer’s IVISense Transferrin Receptor 750 fluorescent probe (Transferrin-Vivo) is a NIR-labeled in vivo imaging probe that detects transferrin receptor levels associated with an altered metabolic need for iron in cancer and inflammatory cells. IVISense Transferrin Receptor 750 fluorescent agent also detects normal transferrin receptor levels in the liver as well as decreased expression due to altered iron metabolism associated with drug-induced liver injury.

For research use only. Not for use in diagnostic procedures.

Part Number
List Price
Your Price
672.00 USD
Buy Now

Please enter valid quantity

Please log in to add favorites.



IVISense Transferrin Receptor 750 is a targeted fluorescent imaging probe, where recombinant transferrin is conjugated to an IVISense fluorescent dye, designed to bind to transferrin receptors (TfRs) expressed in cancer cells. Because of rapid cell division and stringent demand for iron (for heme synthesis), many cancer cell types overexpress TfRs. It has been used as a targeting agent for cancer cells. In addition, TfR accumulates in locals of inflammation due to the leakage of plasma proteins and to the expression of TfR receptors by inflammatory cells. During inflammation monocytes leave the blood and differentiate into macrophages at the extravascular tissues, macrophages express surface Tf receptors.


Fluorescent Agent Type Targeted
Product Brand Name IVISense
Quantity in a Package Amount 1.0 Units
Shipping Condition Blue Ice
Resources, Events & More
  • All


In Vivo Imaging Solutions eBook

Researchers trust our in vivo imaging solutions to give them reliable, calibrated data that reveals pathway characterization and therapeutic efficacies for a broad range of indications. Our reagents, instruments, and applications support have helped hundreds of research projects over the years. And our hard-earned expertise makes us a trusted provider of pre-clinical imaging solutions— with more than 9,000 peer reviewed articles as proof.



Best Practices for Designing An Effective In Vivo Fluorescence Imaging Study

Fluorescence molecular imaging is the visualization of cellular and biological function in vivo to gain deeper insights into disease processes and treatment effects. Designing an effective study from the beginning can help save time and resources.

Learn about several important best practices, from proper probe selection to study design to imaging technique tips and tricks needed to generate meaningful biological information from your in vivo fluorescence imaging studies.

PDF 507 KB


Combined efficacy & toxicity imaging following acute 5-FU treatment of HT-29 tumor xenografts

Cancer chemotherapy can produce severe side effects such as suppression of immune function and damage to heart muscle, gastrointestinal tract, and liver. If serious enough, tissue injury can be a major reason for late stage termination of drug discovery research projects, so it is becoming more important to integrate safety/toxicology assessments earlier in the drug development process. There are a variety of traditional serum markers, tailored mechanistically to specific tissues, however there are no current non-invasive assessment tools that are capable of looking broadly at in situ biological changes in target and non-target tissue induced by chemical insult.


White Paper

The Role of In Vivo Imaging in Drug Discovery and Development

The primary goal of preclinical imaging is to improve the odds of clinical success and reduce drug discovery and development time and costs. Advances in non-invasive in vivo imaging techniques have raised the use of animal models in drug discovery and development to a new level by enabling quick and efficient drug screening and evaluation. Read this White Paper to learn how preclinical in vivo imaging helps to ensure that smart choices are made by providing Go/No-Go decisions and de-risking drug candidates early on, significantly reducing time to the clinic and lowering costs all while maximizing biological understanding.

PDF 547 KB